-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2

Benzinga·08/11/2026 20:07:07
Listen to the news
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ:HCAT) with a Neutral and lowers the price target from $2.5 to $2.